Acadian Asset Management LLC decreased its holdings in shares of Cigna Corp (NYSE:CI) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 350,822 shares of the health services provider’s stock after selling 9,566 shares during the quarter. Acadian Asset Management LLC owned approximately 0.09% of Cigna worth $71,740,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Braun Bostich & Associates Inc. acquired a new stake in Cigna in the 4th quarter worth approximately $26,000. Garrett Wealth Advisory Group LLC bought a new position in shares of Cigna in the third quarter valued at approximately $30,000. Knuff & Co LLC bought a new position in shares of Cigna in the third quarter valued at approximately $30,000. Optimum Investment Advisors lifted its stake in shares of Cigna by 258.6% in the third quarter. Optimum Investment Advisors now owns 208 shares of the health services provider’s stock worth $32,000 after buying an additional 150 shares during the last quarter. Finally, Lowe Wealth Advisors LLC acquired a new stake in shares of Cigna in the fourth quarter worth $44,000. Institutional investors and hedge funds own 87.48% of the company’s stock.
NYSE CI opened at $220.34 on Friday. The company’s fifty day moving average is $206.56 and its two-hundred day moving average is $181.29. Cigna Corp has a 52-week low of $141.95 and a 52-week high of $224.64. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.43 and a quick ratio of 0.63. The firm has a market capitalization of $78.54 billion, a price-to-earnings ratio of 16.41, a P/E/G ratio of 1.00 and a beta of 0.79.
Cigna (NYSE:CI) last announced its quarterly earnings data on Thursday, February 6th. The health services provider reported $4.31 EPS for the quarter, beating the Zacks’ consensus estimate of $4.20 by $0.11. Cigna had a net margin of 3.32% and a return on equity of 14.69%. The business had revenue of $36.54 billion during the quarter, compared to analyst estimates of $35.20 billion. During the same quarter in the prior year, the business earned $2.46 earnings per share. The firm’s revenue for the quarter was up 165.7% on a year-over-year basis. As a group, sell-side analysts expect that Cigna Corp will post 18.51 earnings per share for the current fiscal year.
In other news, insider Timothy C. Wentworth sold 12,436 shares of the stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $199.15, for a total value of $2,476,629.40. Following the completion of the transaction, the insider now owns 108,214 shares in the company, valued at approximately $21,550,818.10. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Steven B. Miller sold 7,145 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $212.15, for a total transaction of $1,515,811.75. Following the completion of the transaction, the executive vice president now owns 32,071 shares of the company’s stock, valued at approximately $6,803,862.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 51,545 shares of company stock valued at $10,612,704. Insiders own 0.80% of the company’s stock.
A number of research firms recently issued reports on CI. BMO Capital Markets reiterated an “outperform” rating and issued a $252.00 target price on shares of Cigna in a research note on Monday, February 10th. Cowen reissued a “buy” rating and set a $250.00 target price on shares of Cigna in a research report on Monday, December 23rd. SunTrust Banks reissued a “buy” rating and set a $280.00 target price on shares of Cigna in a research report on Friday, February 7th. UBS Group upped their price target on shares of Cigna from $222.00 to $244.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Finally, Raymond James raised their price target on Cigna from $225.00 to $240.00 and gave the company an “outperform” rating in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, two have given a hold rating and sixteen have given a buy rating to the company. Cigna currently has a consensus rating of “Buy” and an average target price of $237.05.
Cigna Company Profile
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
Featured Story: Nikkei 225 Index
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.